

DAFTAR PUSTAKA

- Abdullaev, I. F., Bisailon, J. M., Potier, M., Gonzalez, J. C., Motiani, R. K., & Trebak, M. (2008). Stim1 and orai1 mediate crac currents and store-operated calcium entry important for endothelial cell proliferation. *Circulation Research*, *103*(11), 1289–1299. <https://doi.org/10.1161/01.RES.0000338496.95579.56>
- Afiatin, Khoe, L. C., Kristin, E., Masytoh, L. S., Herlinawaty, E., Werayingyong, P., Nadjib, M., Sastroasmoro, S., & Teerawattananon, Y. (2017). Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia. *PLoS ONE*, *12*(5), 1–10. <https://doi.org/10.1371/journal.pone.0177436>
- Agarwal, N., & Prchal, J. T. (2008). Erythropoietic Agents and the Elderly. *Semin Hematol*, *45*(4), 267–275. <https://doi.org/10.1053/j.seminhematol.2008.06.007.Erythropoietic>
- Ahmed, N., Mahmoud, A., Zaki, N., & Genedy, A. (2023). Erythropoietin resistance in patients with regular hemodialysis in Sohag university hospital. *Journal of Biochemical and Clinical Genetics*, *6*(January), 14–21. <https://doi.org/10.24911/jbcgenetics/183-1670609060>
- Alnaeeli, M., & Noguchi, C. T. (2015). *Redefining the Boundaries of the Immunometabolism Territory*. *June*, 153–157.
- Alsabbagh, F. f., Mosa, A. U., Abo Almaali, H. M., & Jafer, H. S. (2024). The Impact of Genetic Polymorphisms in (STIM1 and ORAI1) on Erythropoietin Resistance in Patients with Chronic Renal Failure on Hemodialysis in Iraq. *Journal of Contemporary Medical Sciences*, *10*(1), 86–92. <https://doi.org/10.22317/jcms.v10i1.1495>
- Alves, M. T., Vilaça, S. S., Carvalho, M. das G., Fernandes, A. P., Dusse, L. M. S. A., & Gomes, K. B. (2015). Resistance of dialyzed patients to erythropoietin. *Revista Brasileira de Hematologia e Hemoterapia*, *37*(3), 190–197. <https://doi.org/10.1016/j.bjhh.2015.02.001>
- Angin, M. P., & Cindy, L. (2021). *Erythropoietin Stimulating Agent pada Pasien Hemodialisa di RSUD Pringsewu*. *4*(1), 53–60.
- Arenda Reka Narima, S. (2016). *Hubungan Asupan Zat Besi, Asam Folat, Vitamin B12 dan Vitamin C dengan Kadar Hemoglobin Siswa di SMP*. *4*.
- Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, *23*(10), 1631–1634. <https://doi.org/10.1681/ASN.2011111078>
- Bae, M. N., Kim, S. H., Kim, Y. O., Jin, D. C., Song, H. C., Choi, E. J., Kim, Y. L., Kim, Y. S., Kang, S. W., Kim, N. H., Yang, C. W., & Kim, Y. K. (2015). Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients. *PLoS ONE*, *10*(11), 1–13.

<https://doi.org/10.1371/journal.pone.0143348>

- Bailey, J., Oliveri, A., & Levin, E. (2013). Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. *Bone*, 23(1), 1–7. <https://doi.org/10.1007/s00467-011-1775-3>.Hypertension
- Bamgbola, Oluwatoyin F. (2011). Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. *Kidney International*, 80(5), 464–474. <https://doi.org/10.1038/ki.2011.179>
- Bamgbola, Oluwatoyin Fatai, Kaskel, F. J., & Coco, M. (2009). Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. *Pediatric Nephrology*, 24(3), 571–579. <https://doi.org/10.1007/s00467-008-0954-3>
- Brockmoller, J., Kochling, J., Weber, W., Looby, M., Roots, I., & Neumayer, H.-H. (1992). The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. *British Journal of Clinical Pharmacology*, 34(6), 499–508.
- Brugnara, C., Schiller, B., & Moran, J. (2006). Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. *Clinical and Laboratory Haematology*, 28(5), 303–308. <https://doi.org/10.1111/j.1365-2257.2006.00812.x>
- Buckner, C. A., Lafrenie, R. M., Dénomée, J. A., Caswell, J. M., Want, D. A., Gan, G. G., Leong, Y. C., Bee, P. C., Chin, E., Teh, A. K. H., Picco, S., Villegas, L., Tonelli, F., Merlo, M., Rigau, J., Diaz, D., Masuelli, M., Korrapati, S., Kurra, P., ... Mathijssen, R. H. J. (2016). We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 % . *Intech*, 11(tourism), 13.
- Carrero, J. J., Cabezas-rodríguez, I., Qureshi, A. R., Floege, J., Ketteler, M., London, G., Locatelli, F., Memmos, D., Goldsmith, D., Ferreira, A., Nagy, J., Teplan, V., Martínez-salgado, C., Fernández-martín, J. L., & Zoccali, C. (2018). *Original article Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients*. 8(5), 520–527.
- Chadha, V. K. (2006). *Sample size determination in health studies*. 55–62.
- Chen, Y. T., Lin, C. C., Huang, P. H., & Li, S. Y. (2024). Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus. *Journal of the Formosan Medical Association*, 123(5), 606–612. <https://doi.org/10.1016/j.jfma.2024.01.013>
- Chinudomwong, P., Binyasing, A., Trongsakul, R., & Paisooksantivatana, K. (2020). Diagnostic performance of reticulocyte hemoglobin equivalent in assessing the iron status. *Journal of Clinical Laboratory Analysis*, 34(6), 1–7. <https://doi.org/10.1002/jcla.23225>

- Chung, M., Moorthy, D., Hadar, N., Salvi, P., C.Iovin, R., & Lau, J. (2012). *Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic* (Issue 83). Agency for Healthcare Research and Quality, US.
- Cook, J. D. (2005). Diagnosis and management of iron-deficiency anaemia. *Best Practice and Research: Clinical Haematology*, 18(2 SPEC. ISS.), 319–332. <https://doi.org/10.1016/j.beha.2004.08.022>
- Crews, D. C., Bello, A. K., & Saadi, G. (2019). Burden, Access, and Disparities in Kidney Disease. *Canadian Journal of Kidney Health and Disease*, 6. <https://doi.org/10.1177/2054358119836124>
- de Oliveira Júnior, W. V., Sabino, A. de P., Figueiredo, R. C., & Rios, D. R. A. (2015). Inflammation and poor response to treatment with erythropoietin in chronic kidney disease. *Jornal Brasileiro de Nefrologia : 'orgao Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia*, 37(2), 255–263. <https://doi.org/10.5935/0101-2800.20150039>
- Dedi, S., Teguh akbar, B., Galih, J., & Suharjiman. (2022). *Kejadian Anemia Berdasarkan Asupan Energi, Vitamin B6, Vitamin B12, Vitamin C dan Keragaman Makanan pada Anak Sekolah Dasar di MI Pui Kota Cimahi*. <https://doi.org/10.34305/jikbh.v13i1.467>
- Devarajan, P., Chertow, G. M., Susztak, K., Levin, A., Agarwal, R., Stenvinkel, P., Chapman, A. B., & Warady, B. A. (2022). Emerging Role of Clinical Genetics in CKD. *Kidney Medicine*, 4(4), 100435. <https://doi.org/10.1016/j.xkme.2022.100435>
- El-Kannishy, G. M., Megahed, A. F., Tawfik, M. M., El-Said, G., Zakaria, R. T., Mohamed, N. A., Taha, E. M., Ammar, A. A., Abd Eltawab, A. M., & Sayed-Ahmed, N. A. (2018). Obesity may be erythropoietin dose-saving in hemodialysis patients. *Kidney Research and Clinical Practice*, 37(2), 148–156. <https://doi.org/10.23876/j.krcp.2018.37.2.148>
- Emrich, S. M., Yoast, R. E., Zhang, X., Fike, A. J., Wang, Y. H., Bricker, K. N., Tao, A. Y., Xin, P., Walter, V., Johnson, M. T., Pathak, T., Straub, A. C., Feske, S., Rahman, Z. S. M., & Trebak, M. (2023). Orai3 and orai1 mediate crac channel function and metabolic reprogramming in b cells. *ELife*, 12, 1–33. <https://doi.org/10.7554/eLife.84708>
- Feske, S. (2007). Calcium signalling in lymphocyte activation and disease. *Nature Reviews Immunology*, 7(9), 690–702. <https://doi.org/10.1038/nri2152>
- Ford, B. A., Coyne, D. W., Eby, C. S., & Scott, M. G. (2009). Variability of ferritin measurements in chronic kidney disease; implications for iron management. *Kidney International*, 75(1), 104–110. <https://doi.org/10.1038/ki.2008.526>
- Garrido, P., Ribeiro, S., Fernandes, J., Vala, H., Rocha-Pereira, P., Bronze-da-Rocha, E., Belo, L., Costa, E., Santos-Silva, A., & Reis, F. (2016). Resistance to recombinant human erythropoietin therapy in a rat model of chronic kidney

- disease associated anemia. *International Journal of Molecular Sciences*, 17(1). <https://doi.org/10.3390/ijms17010028>
- Gava, A. L., Freitas, F. P. S., Meyrelles, S. S., Silva, I. V., & Graceli, J. B. (2011). Gender-dependent effects of aging on the kidney. *Brazilian Journal of Medical and Biological Research*, 44(9), 905–913. <https://doi.org/10.1590/S0100-879X2011007500101>
- Gomaa, A. A. E., Zeid, A. M. A., Nagy, I. M., & Zahran, A. M. (2025). Clinica Chimica Acta The effect of genetic polymorphisms in STIM1 and ORAI1 on erythropoietin resistance in Egyptian patients with end-stage renal disease. *Clinica Chimica Acta*, 564(August 2024), 119948. <https://doi.org/10.1016/j.cca.2024.119948>
- Grapsa, K. P. and E. (2013). Management of Anemia on Hemodialysis. In *Hemodialysis* (pp. 320–354).
- Guyton. (2016). *Textbook of Medical Physiology: Vol. 13 ed* (13 Ed). Elsevier.
- Haidar, Z., Tri, R., & Ira, P. (2016). *Korelasi Indeks Eritrosit dengan Kadar Ferritin Serum pada Pasien Gagal Ginjal Kronik di Unit Hemodialisis RSUP dr. Sardjito*. 4–7.
- Harber, M. (2014). Practical nephrology. *Practical Nephrology, Nhanes 3*, 1–901. <https://doi.org/10.1007/978-1-4471-5547-8>
- Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., Callaghan, A. O., Lasserson, D. S., & Hobbs, F. D. R. (2016). *Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis*. 1–18. <https://doi.org/10.5061/dryad.3s7rd.Funding>
- Hospital, V. G. (2009). *Erythropoietin hyporesponsiveness : From iron deficiency to iron overload*. 55. <https://doi.org/10.1038/sj.ki.4490858>
- Hwang, D. Y., Chien, S. C., Hsu, Y. W., Kao, C. C., Cheng, S. Y., Lu, H. C., Wu, M. S., & Chang, J. M. (2014). Genetic polymorphisms of ORAI1 and chronic kidney disease in Taiwanese population. *BioMed Research International*, 2014. <https://doi.org/10.1155/2014/290863>
- Indonesia Renal Register. (2018). 11th report Of Indonesian renal registry 2018. *Indonesian Renal Registry (IRR)*, 14–15.
- KDIGO. (2022) Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease, 102 *Kidney International S129* (2022). <https://doi.org/10.1016/j.kint.2022.07.013>
- Jelkmann, W. (2011). *Regulation of erythropoietin production*. 6, 1251–1258. <https://doi.org/10.1113/jphysiol.2010.195057>
- Jeong, K. H., Lee, T. W., Ihm, C. G., Lee, S. H., & Moon, J. Y. (2008). Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.

Experimental and Molecular Medicine, 40(2), 161–166.
<https://doi.org/10.3858/emm.2008.40.2.161>

Joksimovic Jovic, J., Antic, S., Nikolic, T., Andric, K., Petrovic, D., Bolevich, S., & Jakovljevic, V. (2022). Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress. *Oxidative Medicine and Cellular Longevity*, 2022. <https://doi.org/10.1155/2022/9598211>

K/DOQI. (2015a). *KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update*. 66(5), 884–930.
<https://doi.org/10.1053/j.ajkd.2015.07.015>

K/DOQI. (2015b). *KDOQI CLINICAL PRACTICE GUIDELINE FOR HEMODIALYSIS ADEQUACY: 2015 UPDATE Abstract University of Minnesota Department of Medicine*. 66(5), 884–930.
<https://doi.org/10.1053/j.ajkd.2015.07.015>

Kanbay, M., Perazella, M. A., Kasapoglu, B., Koroglu, M., & Covic, A. (2010). Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: Review of causes and management. *Blood Purification*, 29(1), 1–12.
<https://doi.org/10.1159/000245041>

Kao, C. C., Wong, H. S. C., Wang, Y. J., Chou, W. H., Perwitasari, D. A., Wu, M. S., & Chang, W. C. (2021). The role of genetic polymorphisms in STIM1 and ORAI1 for erythropoietin resistance in patients with renal failure. *Medicine*, 100(17), e25243. <https://doi.org/10.1097/MD.00000000000025243>

KDIGO. (2025). *KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) Public Review Draft November 2024. November 2024*.

Kemenkes. (2023). *Kemenkes Resmikan BGSi, Inisiatif Nasional Pertama untuk Deteksi Potensi Penyakit di Masa Depan*.

Killen, J. P., & Brenninger, V. L. (2014). Hydroxocobalamin supplementation and erythropoiesis stimulating agent hyporesponsiveness in haemodialysis patients *Correspondence: ABSTRACT: Background: Long-term haemodialysis patients may be at risk of hydro-*. 19, 164–171.
<https://doi.org/10.1111/nep.12205>

Kimachi, M., Fukuma, S., Yamazaki, S., Yamamoto, Y., Akizawa, T., Akiba, T., Saito, A., & Fukuhara, S. (2015). Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients. *Nephron*, 131(2), 123–130. <https://doi.org/10.1159/000438870>

Kiss, Z., Ambrus, C., Kulcsár, I., & Szegedi, J. (2015). *Effect of angiotensin-converting enzyme gene insertion / deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis*. <https://doi.org/10.1177/1470320314535276>

- Köttgen, A., Pattaro, C., Böger, C. A., Fuchsberger, C., Olden, M., Glazer, N. L., Parsa, A., Gao, X., Yang, Q., Smith, A. V., O'Connell, J. R., Li, M., Schmidt, H., Tanaka, T., Isaacs, A., Ketkar, S., Hwang, S. J., Johnson, A. D., Dehghan, A., ... Fox, C. S. (2010). New loci associated with kidney function and chronic kidney disease. *Nature Genetics*, 42(5), 376–384. <https://doi.org/10.1038/ng.568>
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*, 12(1), 7–11. <https://doi.org/10.1016/j.kisu.2021.11.003>
- Lankhorst, C. E., & Wish, J. B. (2010a). Anemia in renal disease: Diagnosis and management. *Blood Reviews*, 24(1), 39–47. <https://doi.org/10.1016/j.blre.2009.09.001>
- Lankhorst, C. E., & Wish, J. B. (2010b). Blood Reviews Anemia in renal disease : Diagnosis and management. *Blood Reviews*, 24(1), 39–47. <https://doi.org/10.1016/j.blre.2009.09.001>
- Levine, A. P., Chan, M. M. Y., Sadeghi-Alavijeh, O., Wong, E. K. S., Cook, H. T., Ashford, S., Carss, K., Christian, M. T., Hall, M., Harris, C. L., McAlinden, P., Marchbank, K. J., Marks, S. D., Maxwell, H., Megy, K., Penkett, C. J., Mozere, M., Stirrups, K. E., Tuna, S., ... Gale, D. P. (2020). Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy. *Journal of the American Society of Nephrology*, 31(2), 365–373. <https://doi.org/10.1681/ASN.2019040433>
- Liu, Z. Z., Bullen, A., Li, Y., & Singh, P. (2017). Renal oxygenation in the pathophysiology of chronic kidney disease. *Frontiers in Physiology*, 8(JUN), 1–9. <https://doi.org/10.3389/fphys.2017.00385>
- Locatelli, F., Andrulli, S., Memoli, B., Maffei, C., Del Vecchio, L., Aterini, S., De Simone, W., Mandalari, A., Brunori, G., Amato, M., Cianciaruso, B., & Zoccali, C. (2006). Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. *Nephrology Dialysis Transplantation*, 21(4), 991–998. <https://doi.org/10.1093/ndt/gfk011>
- Lorenz, L., Arand, J., Büchner, K., Wacker-Gussmann, A., Peter, A., Poets, C. F., & Franz, A. R. (2015). Reticulocyte haemoglobin content as a marker of iron deficiency. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, 100(3). <https://doi.org/10.1136/archdischild-2014-306076>
- Lu, X., Zhang, J., Wang, S., Yu, Q., & Li, H. (2020). High erythropoiesis resistance index is a significant predictor of cardiovascular and all-cause mortality in Chinese maintenance hemodialysis patients. *Mediators of Inflammation*, 2020. <https://doi.org/10.1155/2020/1027230>
- Macdougall, I. C., Roberts, D. E., Coles, G. A., & Willia, J. D. (1991a). Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin). *Clinical*

Pharmacokinetics, 20(2), 99–113. <https://doi.org/10.2165/00003088-199120020-00002>

Macdougall, I. C., Roberts, D. E., Coles, G. A., & Willia, J. D. (1991b). Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin). In *Clinical Pharmacokinetics* (pp. 99–113). <https://doi.org/10.2165/00003088-199120020-00002>

Marrero, M. B., Venema, R. C., Ma, H., Ling, B. N., & Eaton, D. C. (1998). Erythropoietin receptor-operated Ca²⁺ channels: Activation by phospholipase C- γ 1. *Kidney International*, 53(5), 1259–1268. <https://doi.org/10.1046/j.1523-1755.1998.00887.x>

McIntyre, C., Harper, I., Macdougall, I. C., Raine, A. E., Williams, A., & Baker, L. R. (1997). Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients. *Clinical Nephrology*, 48(6), 371–374.

McLean, E., Cogswell, M., Egli, I., Wojdyla, D., & De Benoist, B. (2009). Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutrition*, 12(4), 444–454. <https://doi.org/10.1017/S1368980008002401>

McMurray, J. J. V., Parfrey, P. S., Adamson, J. W., Aljama, P., Berns, J. S., Bohlius, J., Drüeke, T. B., Finkelstein, F. O., Fishbane, S., Ganz, T., MacDougall, I. C., McDonald, R. A., McMahon, L. P., Obrador, G. T., Strippoli, G. F. M., Weiss, G., & Więcek, A. (2012). Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney International Supplements*, 2(4), 279–335. <https://doi.org/10.1038/kisup.2012.37>

Melissa A. Furlong Dana Boyd Barr, PhD, Mary S. Wolff, PhD, and Stephanie M. Engel, PhD, P. (2016). ORAI1 mutations abolishing store-operated Ca²⁺ entry cause anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID). *Physiology & Behavior*, 176(1), 100–106. <https://doi.org/10.1016/j.jaci.2017.10.031.ORAI1>

Miwa, N., Akiba, T., Kimata, N., Hamaguchi, Y., Arakawa, Y., Tamura, T., & Nitta, K. (2010). *Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency*. 248–255. <https://doi.org/10.1111/j.1751-553X.2009.01179.x>

Mohammed, S., Oakley, L. L., Marston, M., Glynn, J. R., & Calvert, C. (2022). The association of breastfeeding with cognitive development and educational achievement in sub-Saharan Africa: A systematic review. *Journal of Global Health*, 12, 1–10. <https://doi.org/10.7189/jogh.12.04071>

Mudipalli, A., & Zelikoff, J. T. (2017). *Essential and non-essential metals : carcinogenesis, prevention and cancer therapeutics* (Issue July). <https://doi.org/10.1007/978-3-319-55448-8>

- Nangaku, M., Yamaguchi, J., & Tanaka, T. (2015). Recent advances in understanding of chronic kidney disease. *F1000Research*, 4(0), 1–9. <https://doi.org/10.12688/f1000research.6970.1>
- Nasution, F. A., Nasution, A. T., & Nasution, F. G. (2023). Correlation between Erythropoietin Resistance Index and Mortality in Regular Hemodialysis Patients at Haji Adam Malik General Hospital Medan. *Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)*, 5(2), 103–115. <https://doi.org/10.32734/jetromi.v5i2.12550>
- Noble, R., & Taal, M. W. (2019). Epidemiology and causes of chronic kidney disease. *Medicine (United Kingdom)*, 47(9), 562–566. <https://doi.org/10.1016/j.mpmed.2019.06.010>
- Nordheim, E., & Jenssen, T. G. (2021). Chronic kidney disease in patients with diabetes mellitus. *Endocrine Connections*, 10(5), R151–R159. <https://doi.org/10.1530/EC-21-0097>
- Obrador, G. T., Schultheiss, U. T., Kretzler, M., Langham, R. G., Nangaku, M., Pecoits-Filho, R., Pollock, C., Rossert, J., Correa-Rotter, R., Stenvinkel, P., Walker, R., Yang, C. W., Fox, C. S., & Köttgen, A. (2017). Genetic and environmental risk factors for chronic kidney disease. *Kidney International Supplements*, 7(2), 88–106. <https://doi.org/10.1016/j.kisu.2017.07.004>
- Okazaki, M., Komatsu, M., Kawaguchi, H., Tsuchiya, K., & Nitta, K. (2014). Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. *Blood Purification*, 37(2), 106–112. <https://doi.org/10.1159/000358215>
- Okonko, D. O., Marley, S. B., Anker, S. D., Poole-Wilson, P. A., & Gordon, M. Y. (2013). Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction. *International Journal of Cardiology*, 164(3), 359–364. <https://doi.org/10.1016/j.ijcard.2011.07.045>
- Palar, C. O. L. R. S. (2013). Status Besi pada Pasien Penyakit Ginjal Kronik yang Sedang Menjalani Hemodialisis di Blu RSUD Prof. Dr. R. D. Kandou Manado. *E-CliniC*, 1(1), 1–8. <https://doi.org/10.35790/ecl.1.1.2013.3293>
- Pelusi, S., Girelli, D., Rametta, R., Campostrini, N., Alfieri, C., Traglia, M., Dongiovanni, P., Como, G., Toniolo, D., Camaschella, C., Messa, P., Fargion, S., & Valenti, L. (2013). *The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.*
- Pernefri. (2017). *10 th Annual Report Of Indonesian Renal Registry.*
- PERNEFRI. (2011). Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik. In *Journal of Chemical Information and Modeling* (Vol. 53, Issue 9).
- Putten, K. Van Der, Braam, B., Jie, K. E., & Gaillard, C. A. J. M. (2008).

Mechanisms of Disease: Erythropoietin resistance in patients with both heart and kidney failure. *Nature Clinical Practice Nephrology*, 4(1), 47–57. <https://doi.org/10.1038/ncpneph0655>

Rahayu, I., Saida, S. A., & Mardalena, E. (2023). Pengaruh Diabetes Melitus Tipe Ii Terhadap Gagal Ginjal Kronis Di Rsud Meuraxa Kota Banda Aceh. *Jurnal Ilmu Kedokteran Dan Kesehatan*, 10(11), 3329–3334. <https://doi.org/10.33024/jikk.v10i11.10876>

Rasouly, H. M., Groopman, E. E., Heyman-Kantor, R., Fasel, D. A., Mitrotti, A., Westland, R., Bier, L., Weng, C., Ren, Z., Copeland, B., Krithivasan, P., Chung, W. K., Sanna-Cherchi, S., Goldstein, D. B., & Gharavi, A. G. (2019). The burden of Candidate pathogenic variants for kidney and genitourinary disorders emerging from exome sequencing. *Annals of Internal Medicine*, 170(1), 11–21. <https://doi.org/10.7326/M18-1241>

Rosita, L., Jannatin, N., Purwanto, B. D., Ratnaningsih, T., Sukorini, U., Simanjuntak, Z. S., & Yuantari, R. (2021). Type of anemia correlate with ferritin levels in patients with chronic kidney disease (Ckd): A cross sectional study. *Bali Medical Journal*, 10(3), 867–871. <https://doi.org/10.15562/bmj.v10i3.2418>

Rosita, L., Kertia, N., Ratnaningsih, T., Susanti, V. Y., Widyasari, V., & Yuantari, R. (2024). Review Article Erythropoietin Resistance in Dialysis Patients with Chronic Kidney Disease : Scoping Review. *Bangladesh Journal of Medicine Science*, 23(03), 626–631.

Samavat, S., Nafar, M., Khoshdel, A., & Alipour-Abedi, B. (2017). Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: A cross-sectional multicenter study. *Nephro-Urology Monthly*, 9(3). <https://doi.org/10.5812/numonthly.45003>

Santos, E. J. F., Dias, R. S. C., Lima, J. F. de B., Filho, N. S., & Dos Santos, A. M. (2020). Erythropoietin resistance in patients with chronic kidney disease: Current perspectives. *International Journal of Nephrology and Renovascular Disease*, 13, 231–237. <https://doi.org/10.2147/IJNRD.S239151>

Saran, R., Robinson, B., Abbott, K. C., Bragg-gresham, J., Chen, X., Gipson, D., Gu, H., Hirth, R. A., Hutton, D., Jin, Y., Kapke, A., Kurtz, V., Li, Y., McCullough, K., Modi, Z., Morgenstern, H., Mukhopadhyay, P., Pearson, J., Pisoni, R., ... Woodside, K. J. (2020). US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. *American Journal of Kidney Disease*, 75(January), 2019–2020. <https://doi.org/10.1053/j.ajkd.2019.09.003>

Schneider, Gutjahr-Lengsfeld, L., Ritz, E., Scharnagl, H., Gelbrich, G., Pilz, S., Macdougall, I. C., Wanner, C., & Drechsler, C. (2014). Longitudinal assessments of erythropoietin-stimulating agent responsiveness and the association with specific clinical outcomes in dialysis patients. *Nephron - Clinical Practice*, 128(1–2), 147–152. <https://doi.org/10.1159/000367975>

- Schneider, Schneider, Scharnagl, Jardine, Wanner, & C., D. (2013). Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. *BMC Nephrology*, *14*(1), 67.
- Shen, Y., Wang, J., Yuan, J., Yang, L., Yu, F., Wang, X., Zhao, M. H., Zhang, L., Zha, Y., Zhang, L., Wang, X., Yuan, J., Zhou, Q., Yuan, Q., Chen, M., Zhou, X., Fu, S., Li, S., Zha, Y., ... Huang, L. (2021). Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). *BMC Nephrology*, *22*(1), 1–10. <https://doi.org/10.1186/s12882-021-02247-8>
- Silva-Rojas, R., Laporte, J., & Böhm, J. (2020). STIM1/ORAI1 Loss-of-Function and Gain-of-Function Mutations Inversely Impact on SOCE and Calcium Homeostasis and Cause Multi-Systemic Mirror Diseases. *Frontiers in Physiology*, *11*(November). <https://doi.org/10.3389/fphys.2020.604941>
- Singh, N. P., & Garg, N. (1999). *Management of Anemia in Chronic Kidney Disease: Revisited*.
- Squire, L. R. (2009). Store-operated Ca²⁺ entry through ORAI1 is critical for T cell mediated autoimmunity and allograft rejection. *Neuron*, *61*(1), 1–7. <https://doi.org/10.4049/jimmunol.1001796>. Store-operated
- Stauffer, M. E., & Fan, T. (2014). Prevalence of anemia in chronic kidney disease in the United States. *PLoS ONE*, *9*(1), 2–5. <https://doi.org/10.1371/journal.pone.0084943>
- Straat, M., Van Bruggen, R., De Korte, D., & Juffermans, N. P. (2012). Red blood cell clearance in inflammation. *Transfusion Medicine and Hemotherapy*, *39*(5), 353–360. <https://doi.org/10.1159/000342229>
- Tang, P., & Wang, H. (2023). *Regulation of erythropoiesis : emerging concepts and therapeutic implications*. *28*(1), 1–14.
- Tricco, A. C., Lillie, E., Zarin, W., Brien, K. K. O., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Ma, Q., Horsley, T., Weeks, L., Hartling, L., Aldcroft, A., Hons, B. A., Wilson, M. G., & Garritty, C. (2018). *Research and Reporting Methods Prisma Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation*. August 2016. <https://doi.org/10.7326/M18-0850>
- Trung, K. N., Viet, H. T., Hien, H. N. T., Khanh, V. N., Danh, T. T., & Viet, T. Le. (2022). Evaluation of Predicting the Value of the Reticulocyte Hemoglobin Equivalent for Iron Deficiency in Chronic Kidney Disease Patients. *Nephro-Urology Monthly*, *14*(2). <https://doi.org/10.5812/numonthly-121289>
- United States Renal Data System. (2022). *2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States - Incidence, Prevalence, Patient Characteristics, and Treatment Modalities Highlights*. 2(Cvd).
- Vikulova, O. K., Zheleznyakova, A. V., Lebedeva, N. O., Nikitin, A. G., Nosikov, V. V., & Shestakova, M. V. (2017). Genetic factors in the development of

- chronic kidney disease in patients with diabetes mellitus. *Russian Journal of Genetics*, 53(4), 420–432. <https://doi.org/10.1134/S1022795417030140>
- Villamonte-Calanche, W., Orcosupa-Quispe, D., Mendoza-Cabrera, F., Flores-Gonzales, E., Cari-Avalos, L., & Breibat-Timpo, R. (2023). Correlation between serum ferritin, erythrocyte and hemoglobin indices in infants living at 3400 m altitude. *Andes Pediatrica*, 94(6), 705–712. <https://doi.org/10.32641/andespediatr.v94i6.4486>
- Vos, F. E., Schollum, J. B., & Coulter, C. V. (2011). Red Blood Cell Survival in Long-term Dialysis Patients. *YAJKD*, 58(4), 591–598. <https://doi.org/10.1053/j.ajkd.2011.03.031>
- Wacka, E., Wawrzyniak-Gramacka, E., Tylutka, A., Morawin, B., Gutowicz, M., & Zembron-Lacny, A. (2023). The Role of Inflammation in Age-Associated Changes in Red Blood System. *International Journal of Molecular Sciences*, 24(10). <https://doi.org/10.3390/ijms24108944>
- Waldvogel-abramowski, S., Waeber, G., & Buser, A. (2014). *Physiology of Iron Metabolism*. 213–221. <https://doi.org/10.1159/000362888>
- Weiss. (2003). Oncologist New Insights Into Erythropoietin and Epoetin Alfa : *Signal Transduction*, 8(suppl 3), 18–29.
- Widiana, I. G. R., & Kandarini, Y. (2024). *Gangguan Ginjal, Elektrolit, dan Keseimbangan Asam-Basa* (1st ed.). Penerbit buku kedokteran.
- Wish, J. B. (2020). Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged? *Kidney Medicine*, 2(5), 526–528. <https://doi.org/10.1016/j.xkme.2020.08.002>
- Wua, S.-G., Jenga, F.-R., A, S.-Y. W., Sua, C.-Z., Chunga, T.-C., Changb, W.-J., & Changc, H.-W. (1998). Red Blood Cell Osmotic Fragility in Chronically Hemodialyzed Patients. *Nephron*, 28–32.
- Ylenia, I., Viviana, L., Ilaria, M., Francesco, G., Giovanni, T., Graziella, D. A., Alessandro, C., Ugo, T. D., Domenico, S., & Gianluca, T. (2019). In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: A population-based study. *BMC Nephrology*, 20(1), 1–11. <https://doi.org/10.1186/s12882-019-1554-0>
- Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, Q., Liao, Y., Yu, X., Chen, N., Zhang, J. E., Hu, Z., Liu, F., Hong, D., Ma, L., Liu, H., Zhou, X., Chen, J., ... Wang, H. (2012). Prevalence of chronic kidney disease in China: A cross-sectional survey. *The Lancet*, 379(9818), 815–822. [https://doi.org/10.1016/S0140-6736\(12\)60033-6](https://doi.org/10.1016/S0140-6736(12)60033-6)